Atlas Trials

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Clinical trial NCT01332721 · COMPLETED

Trial details

NCT number
NCT01332721
Sponsor
Tracon Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Solid Tumor
Start date
2011-04-01
Primary completion
2012-09-01
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.